Epitalon (Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide bioregulator Epithalamin, developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Biogerontology. It has been studied for telomerase activation, telomere lengthening, antioxidant effects, and melatonin restoration over more than four decades of research. Epitalon is not FDA-approved as a drug. TruVera provides Epitalon through licensed US compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act — available only with a valid prescription from a licensed clinician.

Think of telomeres as the plastic tips on shoelaces — they protect the ends of your chromosomes from fraying. Every time a cell divides, those tips get a little shorter. When they get too short, the cell can no longer divide properly and either stops working (senescence) or dies. This progressive shortening is one of the most well-documented mechanisms of cellular aging. Telomerase is the enzyme that can rebuild telomere length — but it is largely switched off in adult somatic cells. Epitalon has been shown in human cell and clinical studies to upregulate hTERT, the active component of telomerase, effectively lengthening telomeres in aging cells. The 2003 study by Khavinson et al. demonstrated this in human fetal fibroblasts; a 2014 follow-up showed telomere elongation in elderly patients after repeated Epitalon courses.

The most studied and widely used protocol is a 10-day course of subcutaneous injections, administered once or twice per year — typically spring and autumn. Daily doses in research protocols range from 5 mg to 10 mg per injection. Some clinicians also use intranasal delivery for patients who prefer to avoid injections, though the subcutaneous route has the most supporting data. Your TruVera clinician will review your health history, goals, and preferences and tailor a protocol appropriate for your situation. Compounded Epitalon is provided with detailed administration instructions and care-team support throughout your course.

Epitalon's benefits are largely cumulative and work at the cellular level, so subjective changes often emerge gradually rather than acutely. Some patients report improvements in sleep quality and energy within the first course (10 days to a few weeks); others notice more significant changes after a second course months later. Measurable biomarker changes — such as oxidative stress markers or, in specialized labs, telomere length assessments — are typically evaluated over three to twelve months. Your care team will check in throughout your protocol to track progress and adjust as needed.

Epitalon has been very well tolerated across decades of Russian clinical use and peer-reviewed safety studies involving thousands of patients. The most commonly reported adverse event is mild, transient injection-site reaction — redness or slight discomfort that resolves within hours. No significant systemic adverse effects have been reported in the published literature at therapeutic doses. Because Epitalon has not completed US clinical trials, comprehensive long-term safety data in Western populations is limited. Your TruVera clinician will review your complete health history, medications, and any contraindications before prescribing.

Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. Because Epitalon is most effective when used in consistent courses, if you are considering canceling due to questions about your protocol, we encourage you to message your care team first. Adjustments to dosing, timing, or delivery route can often address concerns before discontinuation is necessary.